Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rindopepimut/GM-CSF with adjuvant temozolomide in newly diagnosed EGFRvIII-positive glioblastoma
2012-002272-14Phase 2Active
- Sponsor
- Celldex Therapeutics
- Start
- Dec 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rindopepimut, sargramostim and temozolomide in glioblastoma (GBM) (2 arms), sponsored by Celldex Therapeutics. Primary endpoint: Overall survival rate at 24 months post-randomization. Started Dec 2012; status: active.
02
Drugs
rindopepimutsargramostimtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2012-002272-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002272-14.